Effectiveness and safety of capecitabine with or without bevacizumab as maintenance therapy in metastatic colorectal cancer: Real-world evidence from Vietnam
Nội dung chính của bài viết
Tóm tắt
This retrospective cohort study evaluated the effectiveness and safety of capecitabine-based maintenance therapy in 182 Vietnamese patients with recurrent or metastatic colorectal cancer who achieved disease control after first-line CAPOX plus bevacizumab. Among them, 114 received bevacizumab-capecitabine and 68 received capecitabine alone. Median progression-free survival and overall survival for the whole cohort were 7.9 and 29.6 months, respectively. Compared with capecitabine monotherapy, bevacizumab-capecitabine maintenance was associated with significantly longer progression-free survival (11.2 vs. 5.5 months) and overall survival (36.5 vs. 23.5 months). In multivariable analysis, capecitabine monotherapy was independently associated with a higher risk of progression and death, while response to first-line treatment predicted longer progression-free survival and a higher number of metastatic sites was associated with worse overall survival. Both regimens were generally well tolerated, with most adverse events being grade 1-2 and no treatment-related death. These findings suggest that bevacizumab plus capecitabine is an effective and tolerable maintenance strategy for appropriately selected patients with metastatic colorectal cancer in routine Vietnamese clinical practice.
Chi tiết bài viết
Từ khóa
Metastatic colorectal cancer, capecitabine, bevacizumab, maintenance therapy, Vietnam, real-world study
Tài liệu tham khảo
2. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019; 69(1): 7-34.
3. Zeineddine FA, Zeineddine MA, Yousef A, et al. Survival improvement for patients with metastatic colorectal cancer over twenty years. Npj Precis Oncol. 2023; 7(1): 16.
4. Song Y, Mao Q, Zhou M, Liu CJ, Kong L, Hu T. Effectiveness of bevacizumab in the treatment of metastatic colorectal cancer: a systematic review and meta-analysis. BMC Gastroenterol. 2024; 24(1): 58.
5. Weickhardt A, Wells K, Messersmith W. Oxaliplatin-Induced Neuropathy in Colorectal Cancer. J Oncol. 2011; 2011:1-7.
6. Berry SR, Cosby R, Asmis T, Chan K, Hammad N, Krzyzanowska MK. Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol. 2015; 26(3): 477-485.
7. Tournigand C, Cervantes A, Figer A, et al. OPTIMOX1: A Randomized Study of FOLFOX4 or FOLFOX7 With Oxaliplatin in a Stop-and-Go Fashion in Advanced Colorectal Cancer-A GERCOR Study. J Clin Oncol. 2006; 24(3): 394-400.
8. Simkens LHJ, Van Tinteren H, May A, et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. The Lancet. 2015; 385(9980): 1843-1852.
9. Adams RA, Meade AM, Seymour MT, et al. Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet Oncol. 2011; 12(7): 642-653.
10. Chibaudel B, Maindrault-Goebel F, Lledo G, et al. Can Chemotherapy Be Discontinued in Unresectable Metastatic Colorectal Cancer? The GERCOR OPTIMOX2 Study. J Clin Oncol. 2009; 27(34): 5727-5733.
11. Schwartz LH, Litière S, de Vries E, et al. RECIST 1.1-Update and clarification: From the RECIST committee. Eur J Cancer Oxf Engl 1990. 2016; 62:132-137.
12. Freites-Martinez A, Santana N, Arias-Santiago S, Viera A. Using the Common Terminology Criteria for Adverse Events (CTCAE - Version 5.0) to Evaluate the Severity of Adverse Events of Anticancer Therapies. Actas Dermosifiliogr. 2021; 112(1): 90-92.
13. Luo HY, Li YH, Wang W, et al. Single-agent capecitabine as maintenance therapy after induction of XELOX (or FOLFOX) in first-line treatment of metastatic colorectal cancer: randomized clinical trial of efficacy and safety. Ann Oncol. 2016; 27(6): 1074-1081.
14. Masi G, Salvatore L, Boni L, et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol Off J Eur Soc Med Oncol. 2015; 26(4): 724-730.
15. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol. 2013; 14(1): 29-37.
16. Stein A, Schwenke C, Folprecht G, Arnold D. Effect of Application and Intensity of Bevacizumab-based Maintenance After Induction Chemotherapy With Bevacizumab for Metastatic Colorectal Cancer: A Meta-analysis. Clin Colorectal Cancer. 2016; 15(2): e29-39.
17. Huang W, Zhang H, Tian Y, Cha Y, Xiong H, Yuan X. Efficacy and safety analysis of bevacizumab combined with capecitabine in the maintenance treatment of RAS‐mutant metastatic colorectal cancer. J Clin Pharm Ther. 2022; 47(4): 531-538.
18. Ma H, Wu X, Tao M, et al. Efficacy and safety of bevacizumab-based maintenance therapy in metastatic colorectal cancer: A meta-analysis. Medicine (Baltimore). 2019; 98(50): e18227.
19. Benson AB, Venook AP, Adam M, et al. Colon Cancer, Version 3.2024, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Cancer Netw JNCCN. 2024; 22(2 D): e240029.
20. Cervantes A, Adam R, Roselló S, et al. Metastatic colorectal cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol Off J Eur Soc Med Oncol. 2023; 34(1): 10-32.
21. Vietnam Ministry of Health. Guidelines for Diagnosis and Treatment of Colorectal Cancer. Decision No. 2549/QD-BYT (in Vietnamese). Published online April 19, 2018.
22. Ge Y, Xiang R, Ren J, Song W, Lu W, Fu T. A Nomogram for Predicting Multiple Metastases in Metastatic Colorectal Cancer Patients: A Large Population-Based Study. Front Oncol. 2021; 11:633995.
23. Huang SC, Chang SC, Jiang JK, Su YT. Prognostic impact of metastatic sites and its metastasectomy in colorectal cancer: a retrospective analysis from a single institution. Int J Colorectal Dis. 2025; 40(1): 150.